The Valley of Death in Discovery
Translational research describes the journey of scientific discoveries from laboratory through clinical testing to population health implementation. This journey comprises three phases: T1 (basic science to clinical translation), T2 (clinical trials to clinical practice), and T3 (clinical practice to population health). Each transition confronts substantial obstacles, with the majority of promising discoveries never reaching patient care.
T1 translation converts laboratory discoveries into clinical interventions. A researcher discovers that a particular metabolite enhances intestinal barrier function in mice. Moving to human application requires establishing safety, measuring biomarkers in humans, and proving clinical benefit. The process consumes years and tens of millions of dollars. Of 5,000 laboratory compounds tested, only 250 proceed to animal testing; of those, only 5 reach human testing; typically only 1 gains regulatory approval.
T2 translation converts proven clinical efficacy into changed clinical practice. Paradoxically, this phase frequently fails despite efficacy evidence. Physician adoption lags years behind trial publication. FMT exemplifies T1 translation success. Decades of microbiome research suggested microbiota transplantation could restore competitive landscapes. Early case series showed dramatic success. RCTs proved FMT superior to antibiotics. Yet T2 translation remains incomplete—FMT remains underutilised despite indication.
T3 translation converts clinical practice recommendations into population health improvements. This requires overcoming implementation barriers, addressing health disparities, and providing feedback loops. Implementation science investigates how to effectively translate evidence into practice.